Search Clinical Trials
Sponsor Condition of Interest |
---|
General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19
Weill Medical College of Cornell University
Post-traumatic Stress Disorder
Moral Injury
It is expected that large numbers of healthcare workers will experience a broad range of
psychological reactions and symptoms including anxiety, depression, moral distress, and
trauma symptoms that will cause both significant suffering as well as occupational and
social impairment. The purpose of... expand
It is expected that large numbers of healthcare workers will experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. The purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers caring for COVID-19 patients. There are two phases of the study. All participants will take part in Phase I, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. Participants will be randomly assigned to the narrative writing intervention or medical music intervention. After Phase I, participants will be re-assessed. Healthcare workers who meet criteria for PTSD will be given the option to participate in Phase II of the study, in which they will be offered a choice between one of two evidence-based treatments for PTSD: Interpersonal Therapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minute sessions scheduled twice weekly. Participants will be allowed to choose a preferred treatment in Phase II. After Phase II participants will complete a final assessment concluding the study. All interventions will be offered using distance technology. Type: Interventional Start Date: Jan 2022 |
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
GeneOne Life Science, Inc.
Pneumonitis
SARS-CoV Infection
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in
the prevention of severe pneumonitis caused by SARS-CoV-2 infection expand
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection Type: Interventional Start Date: May 2021 |
COVID-19 Project ECHO in Nursing Homes
Milton S. Hershey Medical Center
Covid19
Nursing homes are ground zero for the COVID-19 pandemic. Nursing homes are ill-equipped
for the pandemic; though facilities are required to have infection control staff, only 3%
have taken a basic infection control course. Significant research has focused on
infection control in the acute care setting.... expand
Nursing homes are ground zero for the COVID-19 pandemic. Nursing homes are ill-equipped for the pandemic; though facilities are required to have infection control staff, only 3% have taken a basic infection control course. Significant research has focused on infection control in the acute care setting. However, little is known about the implementation of practices and effective interventions in long-term care facilities.The investigators propose an intervention utilizing Project ECHO, an evidence-based telehealth model, to connect Penn State University experts with remote nursing home staff and administrators to proactively support evidence-based infection control guideline implementation. Our study seeks to answer the critical research question of how evidence-based infection control guidelines can be implemented effectively in nursing homes Type: Interventional Start Date: Dec 2020 |
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
City of Hope Medical Center
Asymptomatic COVID-19 Infection Laboratory-Confirmed
Symptomatic COVID-19 Infection Laboratory-Confirmed
Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is
referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against
SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a
therapeutic or prophylactic approach in COVID-19... expand
Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID-19 patients. The goal of this study is to help develop a bank of convalescent plasma in California, especially in medically underserved communities particularly affected by the disease. In parallel, CCP administered to COVID-19 patients will be collected and analyzed to determine whether the antibody profile correlates with clinical outcome. The purpose of this non-therapeutic study is to learn more about the CCP antibody profile and the effect it may have in treating COVID-19 infection. Type: Observational Start Date: Jul 2020 |
St. Jude Tracking of Viral and Host Factors Associated With COVID-19
St. Jude Children's Research Hospital
COVID-19
Coronavirus Infection
Coronavirus
SARS-CoV-2
This is a prospective adaptive cohort study of St. Jude employees to determine the rate
of SARS-CoV-2 infections that are asymptomatic and to evaluate immunological responses to
SARS-CoV-2 infection.
Primary Objectives
- To estimate the proportion of asymptomatic infection with SARS-CoV-2... expand
This is a prospective adaptive cohort study of St. Jude employees to determine the rate of SARS-CoV-2 infections that are asymptomatic and to evaluate immunological responses to SARS-CoV-2 infection. Primary Objectives - To estimate the proportion of asymptomatic infection with SARS-CoV-2 infection in a population of SARS-CoV-2-naïve adult St. Jude employees - To comprehensively map CD4 and CD8 T cell epitopes and response magnitudes to SARS-CoV-2 infection in a population of SARS-CoV-2-naïve adult St. Jude employees who acquire SARS-CoV-2 infection - To measure changes in the CD4 and CD8 response magnitude and function to SARS-CoV-2 infection and/or vaccination in a population of St. Jude employees for up to 48 months after infection and/or vaccination. Secondary Objectives - To establish seroprevalence of SARS-CoV-2-specific antibodies at baseline, and identify the rate of seroconversion to SARS-CoV-2 in a population of presumably naïve adult St. Jude employees - To identify features of T cell responses at baseline and during SARS-CoV-2 infection that are associated with protection against symptomatic or severe COVID-19 disease in a population of adult St. Jude employees - To identify risk factors for long-term protection against COVID-19 in a population of adult St. Jude employees - To evaluate changes in antibody responses to SARS-CoV-2 in a population of St. Jude employees for up to 48 months after SARS-CoV-2 infection and/or vaccination. - To evaluate the saliva antibody and cytokine response to SARS-CoV-2 infection and/or vaccination and identify characteristics that predict protection from subsequent SARS-CoV-2 infection among a population of St. Jude employees followed for up to 48 months after SARS-CoV-2 infection and/or vaccination. - To measure changes in saliva antibody responses to SARS-CoV-2 for up to 48 months after SARS-CoV-2 infection and/or vaccination. Exploratory Objectives - To establish additional immunological features including host immune or receptor polymorphisms associated with response to SARS-CoV-2 infection - To explore SARS-CoV-2 diversity and specific features in a circumscribed population - To describe the presence, characteristics, and proportion of short-term re-infection - To determine if an association between SARS-CoV-2 viral load in nasal swab specimens and COVID-19 symptoms can be identified in a population of adult St. Jude employees who acquire SARS-CoV-2 - To explore the laboratory and clinical response to SARS-CoV-2 vaccine in a population of adult St. Jude employees with and without a history of SARS-CoV-2 infection Type: Observational Start Date: Apr 2020 |
Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)
Vivek Reddy
COVID 19 Cardiac
COVID 16 Arrhythmia
COVID 19 Death
The objective of the study is to estimate the frequency of cardiac arrhythmias and
characterize the mode of death in patients with coronavirus disease (SARS-CoV-2;
COVID-19). The study will also evaluate the long term cardiac outcomes in patients
previously diagnosed with COVID-19.
This is a single-center,... expand
The objective of the study is to estimate the frequency of cardiac arrhythmias and characterize the mode of death in patients with coronavirus disease (SARS-CoV-2; COVID-19). The study will also evaluate the long term cardiac outcomes in patients previously diagnosed with COVID-19. This is a single-center, retrospective/ prospective registry enrolling all COVID-19 positive patients at Mount Sinai Hospital. Cohort 1: Retrospective chart review: 1. Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital will be included. 2. A cohort of 1000 influenza patients will also be evaluated for purpose of comparison. Cohort 2: Prospective data collection of 100 patients who: 1. Were hospitalized for COVID-19 and who had an abnormal echocardiogram during hospitalization. 2. A matched cohort (for age, gender, troponin level, and days since hospital discharge) who did not have abnormalities on their echocardiograms (or who did not undergo echocardiogram) to ascertain that in this unusual disease, subjects did not develop echo abnormalities following hospital discharge. Type: Observational Start Date: Apr 2020 |
A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious...
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
COVID-19
Upper Respiratory Infection
Lower Respiratory Infection
Background:
The COVID-19 outbreak has strained the health care system. New tools are needed for
diagnostic testing and monitoring of people who have the virus. Researchers want to test
a device they hope can screen, detect, and monitor symptoms linked to respiratory
diseases like COVID-19.
Objective:
To... expand
Background: The COVID-19 outbreak has strained the health care system. New tools are needed for diagnostic testing and monitoring of people who have the virus. Researchers want to test a device they hope can screen, detect, and monitor symptoms linked to respiratory diseases like COVID-19. Objective: To evaluate and validate a device that measures breathing, body temperature, heart rate, and tissue oxygenation. Eligibility: Healthy adults ages 18 and older with no flu-like symptoms and no current signs of infection, cough, fever, or sneezing. Design: Participants will have a physical exam. Their vital signs will be taken. Participants will sit in a chair. They will be monitored for 60 to 80 minutes while they do the following tasks: Rest for 10 minutes. They will repeat this after each task. Hold their breath for up to 2 minutes and then rest for 2 minutes. They will do this task 3 times. Pace-breathe with breathing rates of 10, 20, and 30 breaths per minute. They will do this task 2 times. Breathe air that has 5% of carbon dioxide for 5 minutes. During these tasks, data will be collected and recorded with a pulse oximeter, thermometer, respiratory belt, and spirometer. Participants will fill out questionnaires related to their daily activity (medication intake, exercise, smoking, and drinking). Participation will last for 2 to 3 hours. Type: Interventional Start Date: May 2022 |
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
University of Chicago
Multiple Sclerosis
Long COVID
Long Covid19
Obese
Obesity
This study is for people who have multiple sclerosis, acute leukemia (in remission), or
long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as
remembering information, concentrating, or making decisions that affect everyday life.
By doing this study, researchers... expand
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks. Type: Interventional Start Date: Jan 2024 |
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
University of California, San Francisco
COVID-19
The goal of this cluster randomized clinical trial is to test the efficacy of messaging
interventions to increase booster vaccine uptake in adults in the emergency
department(ED). The main question[s] and goals of this study are:
- does the intervention of vaccine messaging increase booster vaccine... expand
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question[s] and goals of this study are: - does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit? - does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit? - considering recent national changes to funding and availability of updated vaccines, the investigators will examine the effects of these changes on vaccine acceptance and uptake in ED populations. Specifically, they will stratify EDs and ED patients according to the ED availability of vaccines, and they will also examine whether costs and availability of vaccines are a deterrent to patient acceptance and uptake of vaccines Type: Interventional Start Date: Jan 2024 |
Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting
EmitBio Inc.
Post COVID-19 Condition (PCC)
Duration of Treatment: 7 days, 2 times per day.
Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and
rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be
followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day... expand
Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36, (+3/-3days). Subjects will receive a weekly televisit during Week 3 / day 15 (+3/-3), Week 4 / day 22 (+3/-3), and Week 5 / day 29 (+3/-3). Type: Interventional Start Date: Oct 2023 |
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
Arizona State University
Vaccine-Preventable Diseases
COVID-19 Pandemic
Health-Related Behavior
Health Knowledge, Attitudes, Practice
Narration
COVID-19 vaccines are available to children over six months, and these vaccines are
powerful tools against this catastrophic pandemic. However, Hispanic/Latino children have
lower COVID-19 vaccination rates than White non-Hispanic children .Our team of health
communication and public health experts... expand
COVID-19 vaccines are available to children over six months, and these vaccines are powerful tools against this catastrophic pandemic. However, Hispanic/Latino children have lower COVID-19 vaccination rates than White non-Hispanic children .Our team of health communication and public health experts proposes a community-based theory-driven intervention that utilizes culturally-grounded narratives from digital storytelling to reduce Hispanic parents' COVID-19 vaccine hesitancy and increase their children's vaccine uptake. Type: Interventional Start Date: Jul 2024 |
REVERSE-Long COVID-19 With Baricitinib Study
Vanderbilt University Medical Center
Post-Acute COVID-19 Syndrome
REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive
impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or
cardiopulmonary symptoms due to Long COVID. expand
REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID. Type: Interventional Start Date: Oct 2024 |
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
Northwestern University
Rheumatic Diseases
COVID-19 Vaccine
COVID-19
SLE
To establish the efficacy of a community-based POL (Popular Opinion Leader) intervention
with two different trainings designed to increase COVID-19 vaccine and booster uptake and
reduce hesitancy among social networks of Black individuals with rheumatic conditions.
The investigators will also determine... expand
To establish the efficacy of a community-based POL (Popular Opinion Leader) intervention with two different trainings designed to increase COVID-19 vaccine and booster uptake and reduce hesitancy among social networks of Black individuals with rheumatic conditions. The investigators will also determine the structure and composition of the personal and outreach social networks of POLs. Type: Interventional Start Date: Mar 2024 |
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023...
ModernaTX, Inc.
COVID-19
The goal of this observational study is to analyze binding antibody levels in adults in
the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent
boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5). expand
The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5). Type: Observational Start Date: Mar 2023 |
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
Arcturus Therapeutics, Inc.
COVID-19
SARS-CoV-2 Infection
Corona Virus Infection
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will
evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying
RNA vaccine candidates against COVID-19 in adults previously vaccinated and not
previously vaccinated against SARS-CoV-2. expand
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2. Type: Interventional Start Date: Aug 2021 |
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents...
ModernaTX, Inc.
SARS-CoV-2
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is
designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273
vaccine administered as primary series... expand
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series and a booster dose (BD) to an adolescent population. The study will also evaluate the safety and immunogenicity of an mRNA-1273.222 vaccine against the SARS-CoV- 2 omicron variant as a primary series. Type: Interventional Start Date: Dec 2020 |
Vitamin D for COVID-19 Trial
Brigham and Women's Hospital
COVID-19
The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical
trial in 2024 men and women from across the U.S. and Mongolia to investigate whether
taking a daily dietary supplement of vitamin D vs. placebo for 4 weeks reduces the rate
of seeking healthcare for symptoms or concerns... expand
The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical trial in 2024 men and women from across the U.S. and Mongolia to investigate whether taking a daily dietary supplement of vitamin D vs. placebo for 4 weeks reduces the rate of seeking healthcare for symptoms or concerns related to COVID-19 in participants recently diagnosed with COVID-19, and reduces the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in household contacts of individuals with newly diagnosed COVID-19. Type: Interventional Start Date: Dec 2020 |
OUR Stress/ Emotion Management for Black/African American Women With Hypertension
Ohio State University
Stress, Psychological
Covid-19 is an additional stressor Black women have to deal with that may interfere with
hypertension self-care management. Social connectedness is a source of resilience for
Black women to promote mental and physical health. Unfortunately, in the face of the
Covid-19 pandemic, social distancing is... expand
Covid-19 is an additional stressor Black women have to deal with that may interfere with hypertension self-care management. Social connectedness is a source of resilience for Black women to promote mental and physical health. Unfortunately, in the face of the Covid-19 pandemic, social distancing is a challenge further isolating Black women from their networks. How is social connectedness to manage stress and emotional well-being in a social-distancing society for Black women with hypertension? The research team proposed a synchronous web-based version of Enhanced Co-Created Health Education InterventioN (eCo-CHIN) that build the success and best practices derived from the original intervention. A Covid-19 session will be included as a way of helping Black women to maintain resilience and self-care during stressful times. The eCo-CHIN intervention is innovative and timely because the research team are using a synchronous platform preparing Black women on how to deal with Covid-19 while taking care of self. The primary investigator for this pilot study (Dr. Wright) is a Black Early Stage Investigator and former KL2 (career development) awardee. The interdisciplinary research team has the expertise and resources to deliver this Enhanced Co-CHIN intervention. Type: Interventional Start Date: May 2021 |
ARrest RESpiraTory Failure From PNEUMONIA
Stanford University
Pneumonia
Hypoxemia
Acute Respiratory Failure
COVID-19 Pneumonia
This research study seeks to establish the effectiveness of a combination of an inhaled
corticosteroid and a beta agonist compared to placebo for the prevention of acute
respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia. expand
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia. Type: Interventional Start Date: Jun 2020 |
Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions
National Institute of Dental and Craniofacial Research (NIDCR)
COVID-19
Background:
COVID-19 is a worldwide pandemic and currently there is no effective therapy or vaccine.
SARS-CoV-2, the virus that causes the COVID-19 respiratory infection, appears to be very
contagious however all the modes of transmission are unclear. Transmission may occur in
up to 25 percent... expand
Background: COVID-19 is a worldwide pandemic and currently there is no effective therapy or vaccine. SARS-CoV-2, the virus that causes the COVID-19 respiratory infection, appears to be very contagious however all the modes of transmission are unclear. Transmission may occur in up to 25 percent of cases when there are no symptoms (asymptomatic). Before there are any symptoms, droplet spray during speaking may increase transmission from person to person; most of the spray is saliva. Researchers at the NIH would like to test saliva for the virus before symptoms are reported. Additionally, they would like to examine the importance of using masks to prevent transmission. They hope to better understand how COVID-19 is spread among people and how it can be prevented. For this study they would like to collect samples from the nose (nasopharyngeal swab), mouth (spit sample), eye (conjunctival fluid) and blood to test for the virus and if it is contagious. Objectives: To determine if the SARS-CoV-2 virus is present in saliva in asymptomatic individuals who are COVID-19 positive. To determine if using masks can prevent transmission. Eligibility: People ages 18 and older without symptoms or with mild symptoms (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) who have been in close contact (e.g. live in the same house) with someone who has tested positive for COVID-19 or people who have tested positive for COVID-19 and have mild (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) or no symptoms. Design and Procedures: For screening, interested participants will contact a study team member. The interested participant will be asked to provide documentation of COVID-19 positive status, their symptoms, or their contact to a COVID-19 positive person. Participants will be asked to come to the NIH drive-up COVID-19 testing site or NIH Clinical Center (Bethesda, MD) for 2 or more visits in 15 days for the following procedures: nasal swab for COVID-19 and viral load, verbal symptom assessment, saliva collection, and speaking exercise to capture oral fluid. During this time, participants will also be asked to participate in phone calls with the study staff and to complete questionnaires electronically. Participants will have weekly telephone calls to discuss their symptoms and 2-5 drive-up visits to the NIH within 28 days. If visits are scheduled at the Clinical Center, participants will have the option to participate in providing blood sample(s), a conjunctival swab and 1-2 salivary gland biopsies. If a participant has tested positive, they may be asked to return to the NIH after they have recovered from COVID-19 for additional sampling. The following procedures are part of this research: - Speaking exercise - participants will be asked to read a short script with and without wearing a mask. The droplets they produce while they speak will be collected. - Saliva collection - participants will spit into a cup and have saliva collected from different areas of the mouth. They should not eat 90 minutes before this but drinking water or juice is acceptable. They may have their tongue painted with a sour liquid to increase their saliva. - Nasal swab- participants will have a swab rubbed inside their nose. - Nasopharyngeal swab - participants that are close contacts of COVID-19 positive individual(s) and need a COVID-19 test, will have a swab inserted through the nose to rub the back of their throat. - Questionnaires - participants will complete questionnaires about their symptoms electronically at home. The following procedures are optional for participants to agree to participate in and will be performed in the Clinical Center: - Blood sample(s) - participants will have blood collection via venipuncture. - Conjunctival swab - participants will have the inner lower eyelid wiped with swab. - Minor salivary gland biopsy - participants will have tiny glands in mouth removed. Procedure will be done in the hospital. Participants will be paid up to a total of $300 for the study, based on the number of visits to NIH and the types of procedures performed. Payment will be: $50 on Day 1, Day 15 and at the recovery visit. Participants who agree to the optional conjunctival swab and/or biopsy will be paid $50 for each conjunctival swab (up to 1) and/or $50 for each salivary biopsy (up to 2). If at any time the participants start to have moderate or severe respiratory symptoms, their participation in the study will end and they should seek care with their local provider. Type: Observational Start Date: Apr 2020 |
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The Geneva Foundation
COVID-19
SARS CoV 2 Virus
COVID-19 Pneumonia
COVID-19 Respiratory Infection
COVID-19 Acute Respiratory Distress Syndrome
The primary objective of this effort will be to optimize and operationalize innovative
passive surveillance systems and in parallel, the effort will identify, evaluate, and
transition groundbreaking new technologies in diagnostics for operationalization.
To meet the objective and execute the deliverables... expand
The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in diagnostics for operationalization. To meet the objective and execute the deliverables for this program of effort, the A&M Breathalyzer PROTECT Kiosk will be tested, modified and validated at Brooke Army Medical Center (BAMC). The collaborative efforts between the PI, Dr. Michael Morris at BAMC and Co-Investigator Dr. Tony Yuan at USU- Center for Biotechnology (4D Bio3) will assess the passive detection technology and provide a capability survey of use-case scenarios for different operational settings. Goals: 1. Optimization and operationalize the A&M Breathalyzer PROTECT Kiosk, portable mass spectrometer (MS) Detector for Deployment in Military Operational Medicine Environments. The Breathalyzer will be deployed to BAMC to test its detection capabilities of COVID-19 among symptomatic and asymptomatic COVID-19 carrier vs. those not infected compared to gold standard RT-PCR. 2. Evaluate the passive sensing, breath capture system, built within the A&M Breathalyzer PROTECT Kiosk. The conversion of the active breath capture system, currently requires a straw that the subject breaths into, where then a series of sensors built in the Breathalyzer would automatically sample the exhaled breath within proximity for recent COVID-19 exposure. This task would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities. Type: Observational Start Date: Dec 2023 |
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Timothy Henrich
Long COVID
Post Acute Sequelae of COVID-19
Post-Acute COVID-19
Persistent viral infection with viral reservoirs and detection of circulating spike
protein after the initial acute illness is one potential pathogenic mechanism for Long
COVID. This mechanism may be susceptible to antiviral therapy that blocks viral
replication, which has the potential to alleviate... expand
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population. Type: Interventional Start Date: Apr 2024 |
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
Duke University
Sickle Cell Disease
COVID-19 Vaccine
Vaccine Hesitancy
The goal of this clinical trial is to test an COVID-19 vaccination information video in
adults with sickle cell disease. The main questions it aims to answer are why are some
adults with sickle cell disease hesitant to receive COVID-19 vaccination and whether a
COVID-19 vaccination information video... expand
The goal of this clinical trial is to test an COVID-19 vaccination information video in adults with sickle cell disease. The main questions it aims to answer are why are some adults with sickle cell disease hesitant to receive COVID-19 vaccination and whether a COVID-19 vaccination information video tailored for people with sickle cell disease will reduce vaccine hesitancy. Participants will complete a brief survey before and after watching a short video with information on vaccine safety, efficacy, and the greater impact of COVID-19 infection on people with sickle cell disease. Type: Interventional Start Date: Sep 2023 |
Getting INFORMED and Living Well Among Asian Americans in California
University of California, San Francisco
COVID-19
Well-Being, Psychological
The project is to facilitate pandemic recovery by promoting emotional wellness among
Asian Californians. The intervention includes a 6-week program in which participants may
choose to receive text only or text + Lay Health Worker outreach targeting 600
self-identified Asian Americans residing in California... expand
The project is to facilitate pandemic recovery by promoting emotional wellness among Asian Californians. The intervention includes a 6-week program in which participants may choose to receive text only or text + Lay Health Worker outreach targeting 600 self-identified Asian Americans residing in California who speak/read English, Chinese, Korean, Hmong, or Vietnamese. Type: Interventional Start Date: Mar 2024 |
Inpatient COVID-19 Lollipop Study
University of Wisconsin, Madison
COVID-19
Diagnostic Test
This study is being done to see if collecting saliva samples with a "lollipop" collection
method works as well as nasopharyngeal samples for COVID-19 polymerase chain reaction
(PCR) testing. 225 COVID-positive participants aged 4 years and above admitted to a
hospital in the Madison, Wisconsin metropolitan... expand
This study is being done to see if collecting saliva samples with a "lollipop" collection method works as well as nasopharyngeal samples for COVID-19 polymerase chain reaction (PCR) testing. 225 COVID-positive participants aged 4 years and above admitted to a hospital in the Madison, Wisconsin metropolitan area will be enrolled over a 6 month period. Type: Interventional Start Date: Apr 2023 |
- Previous
- Next